What the FDA labels say about taking them together
Cabazitaxel and nelfinavir
Cabazitaxel's FDA label of October 7, 2025 names nelfinavir in its drug interactions section; the nelfinavir label PlainMeds reads does not name cabazitaxel. The cabazitaxel label: “Strong CYP3A inhibitors may increase plasma concentrations of cabazitaxel.”
Check it at the source: the cabazitaxel FDA label on DailyMed (effective October 7, 2025, Sanofi-Aventis U.S. LLC); the nelfinavir FDA label on DailyMed (effective December 11, 2025, AGOURON).
What does the cabazitaxel label say about nelfinavir?
Cabazitaxel label, drug interactionsStrong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase plasma concentrations of cabazitaxel.
Source: FDA drug label (Jevtana), Sanofi-Aventis U.S. LLC, effective October 7, 2025 (SPL set de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa), via openFDA; the full label on DailyMed
What does the nelfinavir label say about cabazitaxel?
Nelfinavir's label (effective December 11, 2025) does not name cabazitaxel in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (VIRACEPT), AGOURON, effective December 11, 2025 (SPL set e72c2bc6-9462-4a2e-8e1d-b97592376cbd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cabazitaxel | Nelfinavir | |
|---|---|---|
| Labeled for | Prostate cancer | HIV |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once